Preventive therapy for latent tuberculosis infection—the promise and the challenges

International Journal of Infectious Diseases

Volumn 56, Issue , 2017, Pages 68-76

  Fox, G J ^a   Dobler, C C ^a,b   Marais, B J ^c   Denholm, J T ^d,e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c University of Sydney   (Australia)

^d MELBOURNE HEALTH   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Drug therapy; Latent tuberculosis; Mass screening; Mycobacterium tuberculosis; Risk factors; Tuberculosis

Indexed keywords

ISONIAZID; ISONIAZID PLUS RIFAMPICIN; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC PROPHYLAXIS; BACTERIAL TRANSMISSION; COST EFFECTIVENESS ANALYSIS; DECISION SUPPORT SYSTEM; DRUG RESISTANT TUBERCULOSIS; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MASS SCREENING; MEDICATION COMPLIANCE; MIGRANT; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRACTICE GUIDELINE; REVIEW; SKIN TEST; TUBERCULIN TEST; COST BENEFIT ANALYSIS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; IMMUNE TOLERANCE; LATENT TUBERCULOSIS; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85009813187     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2016.11.006     Document Type: Review

References (111)

1. 1 World Health Organization, Global tuberculosis report 2015. 2015, WHO, Geneva.
2. 2 Dye, C., Scheele, S., Dolin, P., Pathania, V., Raviglione, M.C., Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. J Am Med Assoc 282 (1999), 677–686.
3. 3 Marks, G.B., Bai, J., Simpson, S.E., Sullivan, E.A., Stewart, G.J., Incidence of tuberculosis among a cohort of tuberculin-positive refugees in Australia: reappraising the estimates of risk. Am J Respir Crit Care Med 162 (2000), 1851–1854.
4. 4 Getahun, H., Matteelli, A., Chaisson, R.E., Raviglione, M., Latent Mycobacterium tuberculosis infection. N Engl J Med 372 (2015), 2127–2135.
5. 5 Brewer, T.F., Heymann, S.J., To control and beyond: moving towards eliminating the global tuberculosis threat. J Epidemiol Community Health 58 (2004), 822–825.
6. 6 Uplekar, M., Weil, D., Lonnroth, K., Jaramillo, E., Lienhardt, C., Dias, H.M., et al. WHO's new end TB strategy. Lancet 385 (2015), 1799–1801.
7. 7 Rangaka, M.X., Cavalcante, S.C., Marais, B.J., Thim, S., Martinson, N.A., Swaminathan, S., et al. Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection. Lancet 386 (2015), 2344–2353.
8. 8 Lin, P.L., Maiello, P., Gideon, H.P., Coleman, M.T., Cadena, A.M., Rodgers, M.A., et al. PET CT identifies reactivation risk in cynomolgus macaques with latent M. tuberculosis. PLoS Pathog, 12, 2016, e1005739.
9. 9 Barry, C., Boshoff, H., Dartoise, V., Dick, T., Ehrt, S., Flynn, J., et al. The spectrum of latent tuberculosis: rethinking the biology of intervention strategies. Nat Rev Microbiol 7 (2009), 845–855.
10. 10 Trauer, J.M., Moyo, N., Tay, E.L., Dale, K., Ragonnet, R., McBryde, E.S., et al. Risk of active tuberculosis in the five years following infection…15%?. Chest 149 (2016), 516–525.
11. 11 Fox, G.J., Barry, S.E., Britton, W.J., Marks, G.B., Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J 41 (2013), 134–150.
12. 12 Triasih, R., Robertson, C.F., Duke, T., Graham, S.M., A prospective evaluation of the symptom-based screening approach to the management of children who are contacts of tuberculosis cases. Clin Infect Dis 60 (2015), 12–18.
13. 13 Seddon, J.A., Paton, J., Nademi, Z., Keane, D., Williams, B., Williams, A., et al. The impact of BCG vaccination on tuberculin skin test responses in children is age dependent: evidence to be considered when screening children for tuberculosis infection. Thorax 71 (2016), 932–939.
14. 14 Wei, J.L., Bond, J., Sykes, K.J., Selvarangan, R., Jackson, M.A., Treatment outcomes for nontuberculous mycobacterial cervicofacial lymphadenitis in children based on the type of surgical intervention. Otolaryngol Head Neck Surg 138 (2008), 566–571.
15. 15 Machingaidze, S., Wiysonge, C.S., Gonzalez-Angulo, Y., Hatherill, M., Moyo, S., Hanekom, W., et al. The utility of an interferon gamma release assay for diagnosis of latent tuberculosis infection and disease in children: a systematic review and meta-analysis. Pediatr Infect Dis J. 30 (2011), 694–700.
16. 16 Hoff, S.T., Peter, J.G., Theron, G., Pascoe, M., Tingskov, P.N., Aggerbeck, H., et al. Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection. Eur Respir J 47 (2016), 919–928.
17. 17 Getahun, H., Matteelli, A., Abubakar, I., Aziz, M.A., Baddeley, A., Barreira, D., et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 46 (2015), 1563–1576.
18. 18 National Institute of Health and Care Excellence, Tuberculosis: NICE guideline (NG33). 2016, NICE, London.
19. 19 Dorman, S.E., Belknap, R., Graviss, E.A., Reves, R., Schluger, N., Weinfurter, P., et al. Interferon-gamma release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med 189 (2014), 77–87.
20. 20 Farhat, M., Greenaway, C., Pai, M., Menzies, D., False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?. Int J Tuberc Lung Dis 10 (2006), 1192–1204.
21. 21 World Health Organization, Guidelines on the management of latent tuberculosis infection. WHO/HTM/TB/2015. 01. 2014, WHO, Geneva.
22. 22 Smieja, M.J., Marchetti, C.A., Cook, D.J., Smaill, F.M., Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev(2), 2000, CD001363.
23. 23 Adamu, B., Abdu, A., Abba, A.A., Borodo, M.M., Tleyjeh, I.M., Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis. Cochrane Database Syst Rev, 3, 2014, CD008597.
24. 24 Sterling, T.R., Villarino, M.E., Borisov, A.S., Shang, N., Gordin, F., Bliven-Sizemore, E., et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 365 (2011), 2155–2166.
25. 25 Sterling, T.R., Scott, N.A., Miro, J.M., Calvet, G., La Rosa, A., Infante, R., et al. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS 30 (2016), 1607–1615.
26. 26 Villarino, M.E., Scott, N.A., Weis, S.E., Weiner, M., Conde, M.B., Jones, B., et al. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr 169 (2015), 247–255.
27. 27 Menzies, D., Long, R., Trajman, A., Dion, M.J., Yang, J., Al Jahdali, H., et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 149 (2008), 689–697.
28. 28 Churchyard, G.J., Fielding, K.L., Lewis, J.J., Coetzee, L., Corbett, E.L., Godfrey-Faussett, P., et al. A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med 370 (2014), 301–310.
29. 29 Martinson, N.A., Barnes, G.L., Moulton, L.H., Msandiwa, R., Hausler, H., Ram, M., et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 365 (2011), 11–20.
30. 30 Hill, P.C., Dye, C., Viney, K., Tabutoa, K., Kienene, T., Bissell, K., et al. Mass treatment to eliminate tuberculosis from an island population. Int J Tuberc Lung Dis 18 (2014), 899–904.
31. 31 Ferebee, S.H., Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 26 (1970), 28–106.
32. 32 Ferebee, S.H., Mount, F.W., Murray, F.J., Livesay, V.T., A controlled trial of isoniazid prophylaxis in mental institutions. Am Rev Respir Dis 88 (1963), 161–175.
33. 33 Mount, F.W., Ferebee, S.H., The effect of isoniazid prophylaxis on tuberculosis morbidity among household contacts of previously known cases of tuberculosis. Am Rev Respir Dis 85 (1962), 821–827.
34. 34 Ferebee, S.H., Mount, F.W., Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis 85 (1962), 490–510.
35. 35 Comstock, G.W., Ferebee, S.H., Hammes, L.M., A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis 95 (1967), 935–943.
36. 36 Stagg, H.R., Zenner, D., Harris, R.J., Munoz, L., Lipman, M.C., Abubakar, I., Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med 161 (2014), 419–428.
37. 37 Comstock, G.W., How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?. Int J Tuberc Lung Dis 3 (1999), 847–850.
38. 38 American Thoracic Society and Centers for Disease Control and Prevention, Targeted tuberculin testing and treatment of latent tuberculous infection. Am J Respir Crit Care Med 161 (2000), S221–S246.
39. 39 Migliori, G.B., Zellweger, J.P., Abubakar, I., Ibraim, E., Caminero, J.A., De Vries, G., et al. European Union standards for tuberculosis care. Eur Respir J 39 (2012), 807–819.
40. 40 Public Health Agency of Canada, Canadian tuberculosis standards. 7th ed., 2013, Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Canada.
41. 41 Centers for Disease Control and Prevention, American Thoracic Society, Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection—United States, 2003. MMWR Morb Mortal Wkly Rep 52 (2003), 735–739.
42. 42 Chan, P.C., Yang, C.H., Chang, L.Y., Wang, K.F., Lu, B.Y., Lu, C.Y., et al. Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial. Int J Tuberc Lung Dis 16 (2012), 633–638.
43. 43 Hong Kong Chest Service, A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre. Madras/British Medical Research Council. Am Rev Respir Dis 145 (1992), 36–41.
44. 44 Menzies, D., Dion, M.J., Rabinovitch, B., Mannix, S., Brassard, P., Schwartzman, K., Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 170 (2004), 445–449.
45. 45 Sharma, S.K., Sharma, A., Kadhiravan, T., Tharyan, P., Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev(7), 2013, CD007545.
46. 46 Clinicaltrials.gov. Randomized clinical trial comparing 4RIF vs. 9INH for LTBI treatment-effectiveness 2016, Dr Dick Menzies, McGill University. Available at: https://clinicaltrials.gov/ct2/show/NCT00931736?term=NCT00931736&rank=1 (accessed September 8, 2016).
47. 47 Centers for Disease Control and Prevention, Guidelines for the investigation of contacts of persons with infectious tuberculosis. MMWR Recomm Rep 54:RR–15 (2005), 1–47.
48. 48 Simkins, J., Abbo, L.M., Camargo, J.F., Rosa, R., Morris, M.I., Twelve-week rifapentine plus isoniazid versus 9-month isoniazid for the treatment of latent tuberculosis in renal transplant candidates. Transplantation, 2016 [Epub ahead of print], https://www.ncbi.nlm.nih.gov/pubmed/27548035.
49. 49 Ena, J., Valls, V., Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 40 (2005), 670–676.
50. 50 Spyridis, N.P., Spyridis, P.G., Gelesme, A., Sypsa, V., Valianatou, M., Metsou, F., et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 45 (2007), 715–722.
51. 51 Menzies, D., Al Jahdali, H., Al Otaibi, B., Recent developments in treatment of latent tuberculosis infection. Indian J Med Res 133 (2011), 257–266.
52. 52 Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group, Gordin, F., Chaisson, R.E., Matts, J.P., Miller, C., de Lourdes Garcia, M., Hafner, R., et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. J Am Med Assoc 283 (2000), 1445–1450.
53. 53 Centers for Disease Control and Prevention, Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection—New York and Georgia, 2000. MMWR Morb Mortal Wkly Rep 50 (2001), 289–291.
54. 54 Becerra, M., Appleton, S., Franke, M., Chalco, K., Arteaga, F., Bayona, J., et al. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet 377 (2011), 147–152.
55. 55 Denholm, J.T., Leslie, D.E., Jenkin, G.A., Darby, J., Johnson, P.D., Graham, S.M., et al. Long-term follow-up of contacts exposed to multidrug-resistant tuberculosis in Victoria, Australia, 1995–2010. Int J Tuberc Lung Dis 16 (2012), 1320–1325.
56. 56 Bamrah, S., Brostrom, R., Dorina, F., Setik, L., Song, R., Kawamura, L.M., et al. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009–2012. Int J Tuberc Lung Dis 18 (2014), 912–918.
57. 57 Seddon, J.A., Hesseling, A.C., Finlayson, H., Fielding, K., Cox, H., Hughes, J., et al. Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study. Clin Infect Dis 57 (2013), 1676–1684.
58. 58 Schaaf, H.S., Gie, R.P., Kennedy, M., Beyers, N., Hesseling, P.B., Donald, P.R., Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics 109 (2002), 765–771.
59. 59 Adler-Shohet, F.C., Low, J., Carson, M., Girma, H., Singh, J., Management of latent tuberculosis infection in child contacts of multidrug-resistant tuberculosis. Pediatr Infect Dis J 33 (2014), 664–666.
60. 60 Attamna, A., Chemtob, D., Attamna, S., Fraser, A., Rorman, E., Paul, M., et al. Risk of tuberculosis in close contacts of patients with multidrug resistant tuberculosis: a nationwide cohort. Thorax, 64, 2009, 271.
61. 61 Feja, K., McNelley, E., Tran, C.S., Burzynski, J., Saiman, L., Management of pediatric multidrug-resistant tuberculosis and latent tuberculosis infections in New York City from 1995 to 2003. Pediatr Infect Dis J 27 (2008), 907–912.
62. 62 Torre-Cisneros, J., San-Juan, R., Rosso-Fernandez, C.M., Silva, J.T., Munoz-Sanz, A., Munoz, P., et al. Tuberculosis prophylaxis with levofloxacin in liver transplant patients is associated with a high incidence of tenosynovitis: safety analysis of a multicenter randomized trial. Clin Infect Dis 60 (2015), 1642–1649.
63. 63 Centers for Disease Control and Prevention, Latent tuberculosis infection: a guide for primary health care providers. 2016, CDC, Atlanta, GA Available at: http://www.cdc.gov/tb/publications/ltbi/treatment.htm (accessed September 26, 2016).
64. 64 Grzybowski, S., McKinnon, N.E., Tuters, L., Pinkus, G., Philipps, R., Reactivations in inactive pulmonary tuberculosis. Am Rev Respir Dis 93:3P1 (1966), 352–361.
65. 65 Nolan, C.M., Aitken, M.L., Elarth, A.M., Anderson, K.M., Miller, W.T., Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees. Am Rev Respir Dis 133 (1986), 431–436.
66. 66 Grzybowski, S., Fishaut, H., Rowe, J., Brown, A., Tuberculosis among patients with various radiologic abnormalities, followed by the chest clinic service. Am Rev Respir Dis 104 (1971), 605–608.
67. 67 Guelar, A., Gatell, J.M., Verdejo, J., Podzamczer, D., Lozano, L., Aznar, E., et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS 7 (1993), 1345–1349.
68. 68 Antonucci, G., Girardi, E., Raviglione, M.C., Ippolito, G., Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 274 (1995), 143–148.
69. 69 Marais, B.J., Gie, R.P., Schaaf, H.S., Hesseling, A.C., Obihara, C.C., Starke, J.J., et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 8 (2004), 392–402.
70. 70 Comstock, G.W., Livesay, V.T., Woolpert, S.F., The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 99 (1974), 131–138.
71. 71 Winthrop, K.L., Baxter, R., Liu, L., Varley, C.D., Curtis, J.R., Baddley, J.W., et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 72 (2013), 37–42.
72. 72 Dixon, W.G., Watson, K., Lunt, M., Hyrich, K.L., Silman, A.J., Symmons, D.P., et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54 (2006), 2368–2376.
73. 73 Dobler, C.C., McDonald, S.P., Marks, G.B., Risk of tuberculosis in dialysis patients: a nationwide cohort study. PLoS One, 6, 2011, e29563.
74. 74 Meije, Y., Piersimoni, C., Torre-Cisneros, J., Dilektasli, A.G., Aguado, J.M., ESCMID Study Group of Infection in Compromised Hosts, Mycobacterial infections in solid organ transplant recipients. Clin Microbiol Infect 20:Suppl 7 (2014), 89–101.
75. 75 Ergun, I., Ekmekci, Y., Sengul, S., Kutlay, S., Dede, F., Canbakan, B., et al. Mycobacterium tuberculosis infection in renal transplant recipients. Transplant Proc 38 (2006), 1344–1345.
76. 76 Akan, H., Arslan, O., Akan, O.A., Tuberculosis in stem cell transplant patients. J Hosp Infect 62 (2006), 421–426.
77. 77 Leung, C.C., Yu, I.T., Chen, W., Silicosis. Lancet 379 (2012), 2008–2018.
78. 78 Corbett, E.L., Churchyard, G.J., Clayton, T.C., Williams, B.G., Mulder, D., Hayes, R.J., et al. HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners. AIDS 14 (2000), 2759–2768.
79. 79 Jick, S.S., Lieberman, E.S., Rahman, M.U., Choi, H.K., Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 55 (2006), 19–26.
80. 80 Comstock, G.W., Frost revisited: the modern epidemiology of tuberculosis. Am J Epidemiol 101 (1975), 363–382.
81. 81 Dobler, C.C., Flack, J.R., Marks, G.B., Risk of tuberculosis among people with diabetes mellitus: an Australian nationwide cohort study. BMJ Open, 2, 2012, e000666.
82. 82 Jeon, C.Y., Murray, M.B., Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med, 5, 2008, e152.
83. 83 Leung, C.C., Lam, T.H., Chan, W.M., Yew, W.W., Ho, K.S., Leung, G.M., et al. Diabetic control and risk of tuberculosis: a cohort study. Am J Epidemiol 167 (2008), 1486–1494.
84. 84 Kim, S.J., Hong, Y.P., Lew, W.J., Yang, S.C., Lee, E.G., Incidence of pulmonary tuberculosis among diabetics. Tuber Lung Dis 76 (1995), 529–533.
85. 85 van Zyl Smit, R.N., Pai, M., Yew, W.W., Leung, C.C., Zumla, A., Bateman, E.D., et al. Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. Eur Respir J 35 (2010), 27–33.
86. 86 Maurya, V., Vijayan, V.K., Shah, A., Smoking and tuberculosis: an association overlooked. Int J Tuberc Lung Dis 6 (2002), 942–951.
87. 87 Dong, Y.H., Chang, C.H., Lin Wu, F.L., Shen, L.J., Calverley, P.M., Lofdahl, C.G., et al. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: a systematic review and meta-analysis of randomized controlled trials. Chest 145 (2014), 1286–1297.
88. 88 Lee, P.H., Fu, H., Lai, T.C., Chiang, C.Y., Chan, C.C., Lin, H.H., Glycemic control and the risk of tuberculosis: a cohort study. PLoS Med, 13, 2016, e1002072.
89. 89 Jha, P., Jacob, B., Gajalakshmi, V., Gupta, P.C., Dhingra, N., Kumar, R., et al. A nationally representative case–control study of smoking and death in India. N Engl J Med 358 (2008), 1137–1147.
90. 90 Marais, B.J., Ayles, H., Graham, S.M., Godfrey-Faussett, P., Screening and preventive therapy for tuberculosis. Clin Chest Med 30 (2009), 827–846 x.
91. 91 Bibbins-Domingo, K., Grossman, D.C., Curry, S.J., Bauman, L., Davidson, K.W., Epling, J.W. Jr., et al. Screening for latent tuberculosis infection in adults: US Preventive Services Task Force recommendation statement. JAMA 316 (2016), 962–969.
92. 92 Pareek, M., Watson, J.P., Ormerod, L.P., Kon, O.M., Woltmann, G., White, P.J., et al. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis 11 (2011), 435–444.
93. 93 McBryde, E., Denholm, J.T., Risk of active tuberculosis in immigrants: effects of age, region of origin and time since arrival in a low-exposure setting. Med J Aust 197 (2012), 458–461.
94. 94 Wingate, L.T., Coleman, M.S., de la Motte Hurst, C., Semple, M., Zhou, W., Cetron, M.S., et al. A cost–benefit analysis of a proposed overseas refugee latent tuberculosis infection screening and treatment program. BMC Public Health, 15, 2015, 1201.
95. 95 Denholm, J., McBryde, E., Brown, G., Ethical evaluation of immigration screening policy for latent tuberculosis infection. Aust N Z J Public Health 36 (2012), 325–328.
96. 96 Solovic, I., Sester, M., Gomez-Reino, J.J., Rieder, H.L., Ehlers, S., Milburn, H.J., et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 36 (2010), 1185–1206.
97. 97 Dobler, C.C., Martin, A., Marks, G.B., Benefit of treatment of latent tuberculosis infection in individual patients. Eur Respir J 46 (2015), 1397–1406.
98. 98 Alsdurf, H., Hill, P.C., Matteelli, A., Getahun, H., Menzies, D., The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis 16 (2016), 1269–1278.
99. 99 Mills, H.L., Cohen, T., Colijn, C., Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis. Sci Transl Med, 5, 2013, 180ra49.
100. 100 Harstad, I., Heldal, E., Steinshamn, S.L., Garasen, H., Winje, B.A., Jacobsen, G.W., Screening and treatment of latent tuberculosis in a cohort of asylum seekers in Norway. Scand J Public Health 38 (2010), 275–282.
101. 101 Dobler, C., Luu, Q., Marks, G., What patient factors predict physicians’ decision not to treat latent tuberculosis infection in tuberculosis contacts?. PLoS One, 8, 2013, e76552.
102. 102 Dobler, C.C., Marks, G.B., Risk of tuberculosis among contacts in a low-incidence setting. Eur Respir J 41 (2013), 1459–1461.
103. 103 Marais, B., van Zyl, S., Schaaf, H., van Aardt, M., Gie, R., Beyers, N., Adherence to isoniazid preventive chemotherapy: a prospective community based study. Arch Dis Child 91 (2006), 762–765.
104. 104 Horvath, T., Azman, H., Kennedy, G.E., Rutherford, G.W., Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection. Cochrane Database Syst Rev, 3, 2012, CD009756.
105. 105 Dayton, C.S., Ferguson, J.S., Hornick, D.B., Peterson, M.W., Evaluation of an Internet-based decision-support system for applying the ATS/CDC guidelines for tuberculosis preventive therapy. Med Decis Making 20 (2000), 1–6.
106. 106 Menzies, D., Gardiner, G., Farhat, M., Greenaway, C., Pai, M., Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results. Int J Tuberc Lung Dis 12 (2008), 498–505.
107. 107 Dobler, C.C., Martin, A., Marks, G.B., Benefit of treatment of latent tuberculosis infection in individual patients. Eur Respir J 47 (2016), 1594–1595.
108. 108 Dye, C., Glaziou, P., Floyd, K., Raviglione, M., Prospects for tuberculosis elimination. Ann Rev Public Health 34 (2013), 271–286.
109. 109 Zak, D.E., Penn-Nicholson, A., Scriba, T.J., Thompson, E., Suliman, S., Amon, L.M., et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet 387 (2016), 2312–2322.
110. 110 Fox, G.J., Oxlade, O., Menzies, D., Fluoroquinolone therapy for the prevention of multidrug-resistant tuberculosis in contacts. A cost-effectiveness analysis. Am J Respir Crit Care Med 192 (2015), 229–237.
111. 111 Mason, P.H., Degeling, C., Denholm, J., Sociocultural dimensions of tuberculosis: an overview of key concepts. Int J Tuberc Lung Dis 19 (2015), 1135–1143.